Maravai Historical Cash Flow
| MRVI Stock | USD 5.81 0.23 4.12% |
Analysis of Maravai Lifesciences cash flow over time is an excellent tool to project Maravai Lifesciences future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change In Working Capital of 102.7 M or Begin Period Cash Flow of 663.7 M as it is a great indicator of Maravai Lifesciences ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Maravai Lifesciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Maravai Lifesciences is a good buy for the upcoming year.
Maravai |
About Maravai Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Maravai balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Maravai's non-liquid assets can be easily converted into cash.
Maravai Lifesciences Cash Flow Chart
Add Fundamental
Change To Inventory
The increase or decrease in the amount of inventory a company has over a certain period.Net Borrowings
The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Total Cashflows From Investing Activities
The net amount of cash used in or generated from a company's investment activities, such as purchasing or selling assets, during a reporting period.Depreciation
Depreciation indicates how much of Maravai Lifesciences value has been used up. For tax purposes Maravai Lifesciences can deduct the cost of the tangible assets it purchases as business expenses. However, Maravai Lifesciences Holdings must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.Dividends Paid
The total amount of dividends that a company has paid out to its shareholders over a specific period.Most accounts from Maravai Lifesciences' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Maravai Lifesciences current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Maravai Lifesciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. As of now, Maravai Lifesciences' Begin Period Cash Flow is increasing as compared to previous years. The Maravai Lifesciences' current Dividends Paid is estimated to increase to about 250.8 M, while Sale Purchase Of Stock is projected to decrease to (21 K).
| 2021 | 2023 | 2024 (projected) | Capital Expenditures | 14.9M | 65.6M | 68.8M | Dividends Paid | 153.5M | 176.5M | 250.8M |
Maravai Lifesciences cash flow statement Correlations
Click cells to compare fundamentals
Maravai Lifesciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Maravai Lifesciences cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Sale Purchase Of Stock | (227K) | (1.5B) | 1.7M | 0.0 | (20K) | (21K) | |
| Change To Inventory | 106K | (19.1M) | (21.6M) | 9.5M | 649K | 681.5K | |
| Investments | (17.1M) | 6.1M | 105.7M | (267.6M) | (127.9M) | (121.5M) | |
| Change In Cash | 2.8M | 211.5M | 315.1M | 80.9M | (57.2M) | (54.3M) | |
| Net Borrowings | (2.6M) | 196.9M | (6M) | (5.4M) | (4.9M) | (4.7M) | |
| Stock Based Compensation | 1.7M | 24.6M | 10.5M | 18.7M | 34.6M | 36.3M | |
| Free Cash Flow | 7.0M | 126.8M | 353.7M | 518.9M | 60.7M | 57.6M | |
| Change In Working Capital | 2.3M | 35.9M | (176.6M) | (45.1M) | 97.8M | 102.7M | |
| Begin Period Cash Flow | 21.9M | 24.7M | 236.2M | 551.3M | 632.1M | 663.7M | |
| Total Cashflows From Investing Activities | (17.1M) | 6.1M | 105.7M | (267.6M) | (240.9M) | (228.8M) | |
| Other Cashflows From Financing Activities | (1.3M) | 773.7M | (153.0M) | (182.1M) | (55.3M) | (52.5M) | |
| Depreciation | 24.1M | 25.8M | 24.8M | 38.1M | 48.8M | 33.7M | |
| Other Non Cash Items | 2.4M | (7.5M) | (6.2M) | (8.7M) | (690.9M) | (656.4M) | |
| Capital Expenditures | 17.1M | 25.4M | 14.9M | 17.1M | 65.6M | 68.8M | |
| Total Cash From Operating Activities | 24.1M | 152.2M | 368.6M | 536.0M | 126.2M | 221.3M | |
| Change To Account Receivables | (1.9M) | (33.1M) | (70.4M) | (22.3M) | 84.4M | 88.6M | |
| Change To Operating Activities | 1.5M | 9.7M | (17.5M) | (23.6M) | (21.2M) | (20.2M) | |
| Net Income | (5.2M) | 78.8M | 469.3M | 490.7M | (119.0M) | (113.1M) | |
| Total Cash From Financing Activities | (4.2M) | 53.2M | (159.0M) | (187.5M) | (61.1M) | (64.1M) | |
| End Period Cash Flow | 24.7M | 236.2M | 551.3M | 632.1M | 575.0M | 374.2M | |
| Change To Netincome | 477K | (340K) | 45.8M | 320.0M | 368.0M | 386.4M | |
| Change To Liabilities | 2.6M | 78.4M | (7.3M) | (8.7M) | (7.8M) | (7.4M) |
Currently Active Assets on Macroaxis
When determining whether Maravai Lifesciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Maravai Lifesciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Maravai Lifesciences Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Maravai Lifesciences Holdings Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Maravai Lifesciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Maravai Lifesciences. If investors know Maravai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Maravai Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.33) | Earnings Share (1.67) | Revenue Per Share 2.044 | Quarterly Revenue Growth (0.03) | Return On Assets (0.02) |
The market value of Maravai Lifesciences is measured differently than its book value, which is the value of Maravai that is recorded on the company's balance sheet. Investors also form their own opinion of Maravai Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Maravai Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Maravai Lifesciences' market value can be influenced by many factors that don't directly affect Maravai Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Maravai Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Maravai Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Maravai Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.